Dr. Saxena is the Vice President, Microbiology and Process Development. She is an expert in protein structure and function with extensive experience in large and small-molecule drug discovery. Prior to joining Versatope, she was a Director of Protein sciences at Vertex Pharmaceuticals where she worked for 20 years and was responsible for gene expression and biophysical hit validation-optimization of small molecules. While there, she drove the target identification and validation of the lead influenza candidate that was out-licensed to Johnson & Johnson. She has experience with discovery and early development in several areas of research including oncology, neurology, infectious and rare diseases and haemoglobinopathies. Dr. Saxena holds a Ph.D. in Biochemistry from Boston University and has postdoctoral fellowships at Brigham & Women's Hospital/Harvard Medical School and Dana Farber Cancer Research Institute/Harvard Medical School.
Dr. Phan is the Senior Vice President, Portfolio Management & Preclinical Development and has more than 23 years of start-up/biotech and large pharma experience in antibacterial drug discovery and development. Prior to joining Versatope, Dr. Phan was VP of Medicinal Chemistry and Antibacterial Discovery at Warp Drive Bio. Prior to Warp Drive Bio, Dr. Phan held leadership roles at Enanta Pharmaceuticals and at Abbott Laboratories where he led the discovery of numerous antibacterial drugs.
All Rights Reserved |
Versatope Therapeutics
110 Canal St, Fl 4
Lowell, MA 01852